Pfizer Inc. v. Lord

456 F.2d 532, 1972 Trade Cas. (CCH) 73,846
Court of Appeals for the Eighth Circuit·Decided February 15, 1972·No. No. 71-1580·Published·Cited by 45 cases

Opinion

PER CURIAM.

Petitioners, Pfizer Inc., American Cy-anamid Company, Bristol-Myers Company, Squibb Corporation, and The Upjohn Company, manufacturers of drugs, bring this action, seeking a writ of mandamus pursuant to the All Writs Statute, 28 U.S.C. § 1651, and F.R.A.P. Rule 21 directing the Hon. Miles W. Lord, District Judge for the District of Minnesota, to recuse himself from presiding over the above entitled cases. Before instituting this action, petitioners, on September 20, 1971, filed moving papers and affidavits pursuant to 28 U.S.C. § 144, asking Judge Lord to disqualify himself for reasons of bias and prejudice. Judge Lord orally denied the motion for “legal insufficiency.” Although Judge Lord has declined to respond to petitioners’ allegations, respondents, who are plaintiffs in the pending actions, have filed answers objecting to the issuance of the writ. In a separate motion, respondents seek damages and costs allegedly suffered by reason of delay to the proceedings attributable to the filing of petitioners’ action.

We have carefully examined the petition, the underlying joint affidavit, the responses thereto, and portions of the record pertinent to petitioners’ claims. We reach the merits of the petition and deny petitioners the relief requested. We also deny respondents’ motion for damages. We do, however, deem it appropriate to comment on certain aspects of this case.

In a separate action filed contemporaneously, petitioners seek a writ of mandamus as a means of obtaining relief from a discovery order issued by Judge Lord which requires disclosure of certain documents and papers which petitioners claim to be covered by the attorney-client privilege. Our opinion in that controversy, No. 71-1581, 456 F.2d 545, and our opinion in this case are filed together.

I.

BACKGROUND OF THE PRESENT LITIGATION

The present lawsuits involve forty-nine civil antitrust damage actions which have been brought by a number of different categories of plaintiffs, including the United States, states, wholesalers and retailers, insurance companies, private hospitals, agricultural purchasers, and competitors. These actions, and approximately one hundred others, most of which now have been settled, grew out of Federal Trade Commission proceedings instituted in 1958 1 and a criminal anti[534] trust action brought by the United States in 1961.2 3

In substance, the various complaining parties charge that petitioners, individually and in concert, committed fraud on the United States Patent Office in connection with the prosecution of the Con-over patent owned by Pfizer on tetracycline, a broad spectrum antibiotic, and, in addition, that they thereafter conspired to exclude competition and fix antibiotic drug prices in violation of the Sherman Act. The pricing policies of these drug companies were the subject of Federal Trade Commission investigations between 1951 and 1958 and an extensive investigation by a Senate subcommittee, which subsequently reported its findings to the full committee.3

Following the Commission proceedings, several civil antitrust actions were brought against some or all of the petitioners. After the jury verdict in the criminal case, more than one hundred similar actions were commenced. A large number of these cases were venued in the Southern District of New York, some having been commenced in that district and others having been transferred to that district for coordinated pretrial proceedings before the Hon. Inzer B. Wyatt. A majority of these cases were settled with the approval of Judge Wyatt. His opinion approving the settlement is reported as State of West Virginia v. Chas. Pfizer & Co., 314 F.Supp. 710 (S.D.N.Y.1970), aff’d, 440 F.2d 1079 (2d Cir. 1971).

Following the settlement of the bulk of the cases, the Judicial Panel on Multi-district Litigation assigned the non-settling eases to Judge Miles Lord, who had been specially assigned to the Southern District of New York.4 Subsequently, over defendants’ objection, Judge Lord transferred the majority of those cases to the District of Minnesota for trial, pursuant to 28 U.S.C. § 1404 (a). This action was approved by the Second Circuit in Pfizer, Inc. v. Lord, 447 F.2d 122 (2d Cir. 1971).

Judge Wyatt’s opinion outlines the historical background of the prior civil, criminal, and administrative proceedings. We relate some of this history here as background. Cyanamid, in late 1948, produced one of the first broad spectrum antibiotics, chlortetracycline, which it subsequently marketed under the trade name Aureomycin. Cyanamid received a patent (Duggar) on chlortetracycline in 1949 and an improvement patent (Niedercorn) in 1950.

In late 1952, Pfizer claimed discovery of tetracycline, an antibiotic said to be highly superior in some respects to other antibiotics then on the market, through dechlorination of chlortetracy-cline. Pfizer applied for a patent on tetracycline in late 1952; Cyanamid applied for a patent on tetracycline in early 1953. Because of the conflicting applications, the Patent Office declared an “interference.” In two meetings held in November 1953, Pfizer and Cyanamid entered into an agreement by which Cyanamid would license Pfizer under the Duggar and Niedercorn patents. In addition, it was agreed that proofs of priority on tetracycline would be exchanged and that the party found not to have priority would concede priority to the [535] other. The party receiving the patent on tetracycline would then license the other. Thereafter, on the exchange of evidence as to priority, Cyanamid conceded in February of 1954 that Pfizer’s patent (Conover) represented the first discovery of tetracycline. The patent was issued to Pfizer in January 1955.

[534] We are certain that Judges Miles Lord will direct discovery in such a way that pretrial in all non-setiling cases will proceed expeditiously and efficiently and without delay or duplication. In re Antibiotic Drugs, 320 F.Supp. 586, 590-591 (Jud.Pan.Mult.Lit.1970).

[535] Commencing in 1954, Bristol began producing tetracycline and selling it in bulk to Squibb and Upjohn. Bristol, Squibb, and Upjohn sued Pfizer for a declaratory judgment invalidating the patent. The parties reached a settlement whereby licenses under the patent were granted by Pfizer to Bristol, Squibb, and Upjohn.

Free access — add to your briefcase to read the full text and ask questions with AI

Pfizer Inc. v. Lord, 456 F.2d 532, 1972 Trade Cas. (CCH) 73,846 (8th Cir. 1972).

456 F.2d 532 (Pfizer Inc. v. Lord) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

McBeth v. Nissan Motor Corp. USA
921 F. Supp. 1473 (D. South Carolina, 1996)
Crandell v. United States
703 F.2d 74 (Fourth Circuit, 1983)
In Re Corrugated Container Antitrust Litigation
556 F. Supp. 1117 (S.D. Texas, 1982)
In Re Olson
20 B.R. 206 (D. Nebraska, 1982)
In Re United States of America
666 F.2d 690 (First Circuit, 1981)
Monroe Doss v. United States
659 F.2d 863 (Eighth Circuit, 1981)
In Re Coordinated Pretrial Proceedings, Etc.
520 F. Supp. 635 (D. Minnesota, 1981)
International Rectifier Corp. v. American Cyanamid Co.
520 F. Supp. 635 (D. Minnesota, 1981)
Steering Committee v. Mead Corp.
614 F.2d 958 (Fifth Circuit, 1980)
United States v. International Business MacHines Corp.
475 F. Supp. 1372 (S.D. New York, 1979)
Reiter v. Sonotone Corporation
579 F.2d 1077 (Eighth Circuit, 1978)
Reiter v. Sonotone Corp.
579 F.2d 1077 (Eighth Circuit, 1978)
Duplan Corp. v. Deering Milliken, Inc.
444 F. Supp. 648 (D. South Carolina, 1977)
United States v. Pfizer Inc.
560 F.2d 319 (Eighth Circuit, 1977)